Description
Indication & Scope
Retagliptin Phosphate and Metformin Hydrochloride Tablets(I)/(II) improves glycemic control in adult patients with type 2 diabetes mellitus as adjunct to diet and exercise.
- Mechanism: Dual complementary hypoglycemic mechanism. Retagliptin is a DPP-4 inhibitor that prolongs endogenous GLP-1 activity to glucose-dependently boost insulin and suppress glucagon secretion; Metformin reduces hepatic glucose output and improves peripheral insulin sensitivity.
- Drug class: Fixed-dose combination oral anti-diabetic prescription medicine, DPP-4 inhibitor plus biguanide combination agent.
- Clinical use: Simplified single-tablet therapy for type 2 diabetes patients inadequately controlled by single-agent oral hypoglycemic drugs.
| Generic Name | Retagliptin Phosphate and Metformin Hydrochloride Tablets(I)/(II) |
| Brand Name | RuiLinTang |
| Ingredient | Retagliptin Phosphate and Metformin Hydrochloride Tablets(I)/(II) |
| Dosage Form | Tablets |
| Package | (I)50mg Retagliptin Phosphate + 850mg Metformin Hydrochloride*30 tablets/box;
(II)50mg Retagliptin Phosphate + 1000mg Metformin Hydrochloride*30 tablets/box |
| Conditions Treated | Type 2 diabetes mellitus in adult patients requiring blood glucose management |
| Taboos | Severe hypersensitivity to either active ingredient; patients with severe renal impairment, metabolic acidosis or diabetic ketoacidosis; type 1 diabetes patients |
| Place of origin | China |
| Prescription type | Prescription-only |
| Storage Conditions | Store at 25°C±5°C, sealed and protected from moisture |
| Manufacturer | ShengDi Pharmaceutical, Ltd. |
| Registration Authority | National Medical Products Administration (NMPA), China |
| Approval number | H20250015; H20250016 |
| Approval Date | Aug 8, 2025 |
| Shelf Life | 36 months |
How to use ?
Recommended Dose: Once or twice daily oral administration based on baseline blood glucose levels and patient tolerance.
Time: Doses are taken with morning and evening meals to optimize gastrointestinal tolerance.
Instructions for use: Swallow tablets whole with meals; regular renal function monitoring is required for long-term users to reduce lactic acidosis risk.
Interaction: Concomitant use with sulfonylureas or insulin increases hypoglycemia risk; cationic drugs interfere with metformin renal excretion.
Side effects: Mild gastrointestinal discomfort (nausea, diarrhea), nasopharyngitis, headache, and rare lactic acidosis (associated with renal dysfunction).
Important Notice
This product should be administered only by qualified healthcare professionals in accordance with the approved prescribing information and local clinical guidelines. Dosage and administration may vary depending on patient condition, indicatiaon, and regional regulatory requirements.
Packaging & Shipping
Packaging
Original manufacturer’s packaging with secure export carton. Customized export packaging is available upon request.
Shipping Methods
Express Courier (EMS, DHL, FedEx, UPS), Air Freight, and Sea Freight. Cold-chain transportation is available for products requiring temperature-controlled logistics.
Export Support
Certificate of Analysis
GMP Certificate
Commercial Invoice
Packing List & CPP
Cold Chain Logistics
Customs Documentation
Scientific and regulatory sources
FAQ
What is the indication of Retagliptin Phosphate and Metformin Hydrochloride Tablets(I)/(II)?
It improves blood glucose control in adult patients with type 2 diabetes mellitus.
What two drug mechanisms constitute this combination Retagliptin Phosphate and Metformin Hydrochloride Tablets(I)/(II)?
Retagliptin inhibits DPP-4 enzyme; Metformin reduces hepatic glucose production and improves insulin sensitivity.
What is the main advantage of fixed-dose combination tablets of Retagliptin Phosphate and Metformin Hydrochloride Tablets(I)/(II)?
It simplifies medication regimen and improves patient compliance compared with single separate drugs.
What is the main clinical risk of Retagliptin Phosphate and Metformin Hydrochloride Tablets(I)/(II)during long-term use?
Lactic acidosis and increased hypoglycemia risk when combined with insulin or sulfonylureas.
RuiLinTang® | Retagliptin Phosphate and Metformin Hydrochloride Tablets(I)/(II) | Type 2 Diabetes | DengYueRX
INN: Retagliptin Phosphate and Metformin Hydrochloride Tablets(I)/(II)
Indications: Type 2 Diabetes
Dosage Form: Tablets
Strength: (I)50mg + 850mg/tablet; (II)50mg + 1000mg/tablet
